摘要
目的探讨GDP与CHOP方案治疗非特异性外周T细胞淋巴瘤(PTCL-U)的疗效。方法非特异性外周T细胞淋巴瘤患者67例,其中采用GDP方案(吉西他滨+顺铂+强的松)治疗33例(GDP组),采用CHOP方案(环磷酰胺+阿霉素+长春新碱+泼尼松)治疗34例(CHOP组),对比两组的疗效及不良反应。结果 GDP组无进展生存期(PFS)与总生存期(OS)均高于CHOP组(P<0.05)。GDP组总有效率为72.73%(24/33),CHOP组为47.06%(16/34);GDP组近期疗效优于CHOP组(P<0.05);GDP组无进展生存期(PFS)为(9.5±2.9)个月,总生存期(OS)为(15.6±6.2)个月,均明显长于CHOP组的(7.3±2.2)个月、(11.8±4.2)个月;GDP组恶心呕吐严重程度低于CHOP组(P<0.05),两组其余不良反应发生情况比较,差异无统计学意义(P>0.05)。结论 GDP方案治疗外周T细胞淋巴瘤疗效优于传统CHOP方案,恶心呕吐不良反应程度较轻。
Objective To investigate the effects of GDP and CHOP regimens on the treatment of peripheral T-cell lymphoma,unspecified（ PTCL-U）. Methods Sixty-seven patients with PTCL-U were enrolled in the study,33 cases were treated with the GDP regimen（ gemcitabine ＋ cisplatin ＋ prednisone,group GDP）,while 34 cases were treated with the CHOP regimen（ cyclophosphamide ＋ adriamycin ＋ vincristine ＋ prednisone,group CHOP）. The curative effects and adverse reactions were compared between two groups. Results The progression-free survival（ PFS） and overall survival（ OS） of group GDP were higher than those of group CHOP（ P〈0. 05）. The total effective rate of group GDP was72. 73%（ 24 /33）,while of group CHOP was 47. 06%（ 16 /34）; The short-term effects of group GDP was better than that of group CHOP（ P〈0. 05）. The PFS was（ 9. 5 ± 2. 9） months and the OS was（ 15. 6 ± 6. 2） months in group GDP,which were significantly longer than those[（ 7. 3 ± 2. 2） months and（ 11. 8 ± 4. 2） months] in group CHOP. The severity of nausea and vomiting in group GDP was lower than that in group CHOP（ P〈0. 05）,and no statistically significant difference in the other adverse reactions between two groups（ P〉0. 05）. Conclusion The curative effect of GDP regimen on the treatment of PTCL-U patients is superior to that of traditional CHOP regimen,with mild nausea and vomiting.
出处
《广西医学》
CAS
2014年第12期1744-1746,共3页
Guangxi Medical Journal
